# Elixir Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/elixir-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Cambridge, US
- Total disclosed funding: $80M
- Latest round: Series E (May 19, 2009)
- Investors on record: 8

## About

Elixir Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the discovery, development, and commercialization of novel pharmaceuticals for the treatment of metabolic diseases.

## Funding rounds

- Series E, May 19, 2009, $12M — ARCH Venture Partners, Oxford Bioscience Partners, Physic Ventures, MPM BioImpact, Omega Funds
- Series D, Sep 4, 2007, $28M — ARCH Venture Partners, Oxford Bioscience Partners, Physic Ventures, Boston University Community Technology Fund, MPM BioImpact
- Series C, Jun 19, 2006, $18M — ARCH Venture Partners, Oxford Bioscience Partners, CDIB Capital Group, Icon Ventures, MPM BioImpact
- Series B, Feb 1, 2003, $22M — ARCH Venture Partners, Oxford Bioscience Partners, MPM BioImpact

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series B, Series C, Series D, Series E
- Oxford Bioscience Partners (https://capitalatlas.ai/funds/oxford-bioscience-partners) — Series B, Series C, Series D, Series E
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series B, Series C, Series D, Series E
- CDIB Capital Group (https://capitalatlas.ai/funds/cdib-capital-group) — Series C
- Icon Ventures (https://capitalatlas.ai/funds/icon-ventures) — Series C
- Physic Ventures (https://capitalatlas.ai/funds/physic-ventures) — Series D, Series E
- Boston University Community Technology Fund — Series D
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series E